Advertisement

Topics

Boehringer Ingelheim, Lilly, University of Oxford to study empagliflozin in chronic kidney disease

04:00 EDT 17 Apr 2018 | Pharmaceutical Business Review

Boehringer Ingelheim and Eli Lilly and Company have entered into an academic collaboration with the University of Oxford to assess the effects of Jardiance (empagliflozin) on heart and kidney disease in adults with chronic kidney disease.

Original Article: Boehringer Ingelheim, Lilly, University of Oxford to study empagliflozin in chronic kidney disease

NEXT ARTICLE

More From BioPortfolio on "Boehringer Ingelheim, Lilly, University of Oxford to study empagliflozin in chronic kidney disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...